A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Recruiting now · Phase 3

Conditions studied: Hyperphosphatemia Patients on Hemodialysis

In brief

A clinical study to evaluate the long-term safety and efficacy of TS-172 in hyperphosphatemia patients on hemodialysis.

Key facts

Study ID

NCT07285304

Run by

Taisho Pharmaceutical Co., Ltd.

People needed

300

Starts

2025-12-01

Expected to finish

2027-07-31

Last updated by the study team

2025-12-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hyperphosphatemia patients (outpatients) with chronic kidney disease receiving hemodialysis (HD or HDF) 3 times a week for at least 12 weeks prior to Visit 1 (Week -2)
• Patients aged ≥18 years at the time of obtaining informed consent
• Patients who have been prescribed at least one phosphate binder within the approved dosage, and the prescribed drug and dosage regimen should have been unchanged during the last 2 weeks prior to Visit 1 (Week -2)
• Patients with a serum phosphorus concentration of ≥ 3.5 mg/dL and ≤ 7.0 mg/dL at Visit 1 (Week -2) or Visit 2 (Week -1)

You may not qualify if…

• Patients with confirmed serum intact PTH concentration >500 pg/mL at Visit 1 (Week -2)
• Patients who have undergone previous parathyroid intervention (PTx, PEIT, etc.)

Where it is running

• Taisho Pharmaceutical Co., Ltd selected site — Tokyo, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.